NEXGEL, Inc. (NASDAQ:NXGL) Q3 2023 Earnings Call Transcript

NEXGEL, Inc. (NASDAQ:NXGL) Q3 2023 Earnings Call Transcript November 17, 2023

Operator: Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NEXGEL’s Third Quarter 2023 Earnings Conference Call. I will now turn the call over to Valter Pinto, Managing Director of KCSA Strategic Communications, for introductions. Please go ahead.

Valter Pinto: Thank you, operator. Good afternoon, and welcome, everyone, to the NEXGEL Third Quarter 2023 Earnings Conference Call. I’m joined today by Adam Levy, Chief Executive Officer; Adam Drapczuk, Chief Financial Officer of NEXGEL. Before we begin, I’d like to remind everyone that statements made during today’s conference call may be deemed forward-looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of risks, uncertainties and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company’s business, I’ll refer you to the press release issued this evening and filed with the SEC on Form 8-K as well as the company’s reports filed periodically with the SEC.

The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise — unless otherwise required by law. With that, it’s my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead.

Adam Levy : Thank you, Valter, and thank you, everyone, for joining us today to discuss our third quarter 2023 financial and operating results. We are pleased to deliver yet another record revenue quarter in Q3 of $1.22 million, an increase of 115% year-over-year and up slightly as compared to revenue of $1.17 million for the second quarter of 2023. Of note, the $2.3 million in revenue generated in the last 2 quarters exceeds our full year of 2022 revenue. Growth year-over-year was driven by an increase in contract manufacturing. This is our second consecutive quarter of revenue contribution from the acquisition of a 50% interest in the JV with CG Labs. The return on this $500,000 investment into the JV, which we recently made the last payment on has proved to be an excellent mutually beneficial transaction and 1 in which we have quickly realized the benefits.

It has contributed materially to our top line growth and is accretive to the bottom line as well. We also have yet to realize the full benefits to margins as that will come as the new equipment is installed and validated. We expect the first equipment to come online in Q1 of 2024. We recently announced executing the supply agreement with AbbVie to be the supplier of gel pads for their Rapid Acoustic Pulse device. In December of 2021, AbbVie acquired the owner of this technology, Soliton, for $550 million in cash after its RESONIC device demonstrated significant improvement in the appearance of cellulite. After extensive due diligence from AbbVie for many months, our hydrogels were chosen as the required razor to its razor blade model for each procedure to be done.

Our ability to meet the high standards of AbbVie demonstrates the uniqueness of our technology and the fact that a company of their size would select us is something we are very proud of. We expect the RESONIC device to be launched next year. We have been making the necessary preparations to ensure we are fully prepared for this potentially significant and impactful revenue opportunity for NEXGEL. Our branded consumer products grew year-over-year 54% and quarter-over-quarter by 37%. This was led by SilverSeal, which continues to be a hero product for us, consistently gaining popularity and positive reviews. This product is a unique hydrogel dressing for wounds and burns. The sterile silver patches are FDA cleared and have been clinically shown to kill 99% of STAPH, MRSA and STREP.

They’ve also been shown to reduce scarring and pain in wounds. SilverSeal was a behind-the-counter hospital device for many years, and our messaging of hospital-grade product now available for home use has resonated with our consumers. In North America, we are making good progress with Enigma Health for retail distribution. Now that we have fully vetted the audience for our leading products and have gained steady traction in the market, it is time to put these products on shelves. Our active discussions with many leading retailers have been going well, and we realistically could see our products on shelves by this coming summer. Last quarter, we provided an update on our amblyopia patch. We have since launched the product and have shipped to approximately 30 ophthalmology offices and the feedback thus far has been very positive.

We are currently monitoring reorder rates, adoption and consumer feedback to plan the next phase of our rollout strategy. Importantly, we have also made significant strides improving our gross profit, going from a gross loss in Q1 to a gross profit in Q2 and improving again in Q3. Gross margins improved sequentially to 28.1% in Q3 compared to 15% in the prior quarter. Our net loss in the third quarter also continued to trend lower quarter-over-quarter, in line with our goal to become profitable in 2024 from $814,000 in Q1 to $695,000 in Q2 to $552,000 in Q3. Included in our net loss of $552,000 for the third quarter are approximately $95,000 of noncash items. Our cash and cash equivalents decreased from $4.3 million at June 30, 2023 to $3.3 million at September 30, 2023.

The delta between our improved net loss during the quarter and the net cash decrease over the period was related to an increase in accounts receivables and property, plant and equipment investments. As we mentioned last quarter, the customers of CG Converting and Packaging require lengthier payment terms. Their payment terms are closer to 90 days as compared to NEXGEL’s core business customers who typically receive 30-day payment terms. Therefore, AR increased during the period by $208,000. We also invested $361,000 in additional property, plant and equipment during the quarter. Before I turn the call over to Adam, while Q3 was a significant quarter for us — we also have a lot to be excited about as we head into next year. Given our growth into retail in new markets and our branded product line as well as the opportunity to onboard new customers, we have strategically invested in inventory and equipment to increase capacity and automation to meet the significant increase in demand we expect for our proprietary hydrogels in 2024 and beyond.

We expect our revenue to continue to grow year-over-year, margin expansion and the net loss decrease to continue as we move towards profitability, which is always our highest priority. With that, I would like to turn the call over to our CFO, Adam Drapczuk. Adam?

Adam Drapczuk : Thank you, Adam. Today, I’ll review financial highlights of our third quarter 2023 results. For the third quarter of 2023, revenue totaled $1.22 million, an increase of $653,000 or 115% as compared to $568,000 for the same period the year prior. The quarterly increase in overall revenues was primarily due to sales growth in contract manufacturing and branded products year-over-year, including revenue contribution from the joint venture formed with CG Labs. Gross profit for the third quarter of 2023 was $344,000 compared to a gross profit of $148,000 for the same prior year period. Gross profit margin for the third quarter of 2023 was 28.2% compared to 26.1% for the same period the year before. Gross margin increased sequentially to 28.2% during the third quarter of 2023 as compared to 15% during the second quarter of 2023.

Total operating expenses including R&D and SG&A expenses, decreased to $956,000 for the 3 months ended September 30, 2023, compared to $1.19 million for the prior year period. The year-over-year decrease was attributable to a decrease in total SG&A and R&D expenses period-over-period. Net loss for the quarter ended September 30, 2023, improved to $552,000 or $0.10 per basic and diluted share compared to net loss of $1.2 million or $0.22 per basic and diluted share for the same period in 2022. Net loss also improved sequentially to $552,000 during the third quarter of 2023 as compared to $695,000 during the second quarter of 2023. As of September 30, 2023, NEXGEL had approximately $3.3 million of cash. During the quarter, the company invested in capital expenditures for new equipment and increased its capacity at the Texas facility to prepare us to execute our new supply agreements in 2024.

As of November 13, 2023, NEXGEL had 5,717,629 shares of common stock outstanding. I would now like to open the call for questions. Operator?

See also Mario Gabelli Stock Portfolio: 10 Top Stock Picks and 25 Biggest Companies By Net Income In The World.

Q&A Session

Operator: [Operator Instructions] Our first question comes from Naz Rahman with Maxim Group.

Naz Rahman: Congratulations on the progress. I have a few. If I could start — on the supply agreement with AbbVie for the RESONIC product, could you talk a little bit more about the market opportunity and the potential economics to NEXGEL in ’24?

Adam Levy: Sure. Nav, good to hear from you again. So look, we’re under NDA with AbbVie. So I can’t obviously share their forecast. We’re obviously not in control of their launch. But I can say that you really couldn’t ask for a much better partner in a product like this. And I can say that if they are successful, this is extremely significant and impactful revenue for us.

Naz Rahman: Got it. And on kind of a similar note, you also signed a deal with Haleon earlier this year for a product launch by them. Do you have any updates on the product? Or do you have any potential time lines on when we could hear more about the product itself and a potential launch?

Adam Levy: Yes. That product is actually a little bit further off than the AbbVie product. So think about that for — or certainly an update somewhere in mid ’24 as they are probably targeting the end of ’24 has always been kind of our guidance on that product.

Naz Rahman: Got it. That’s helpful. So on those 2 points, now more of like a high-level strategic question I’ve had and then had conversations about is — you obviously had a very, very transformative 2023, and you have a lot of different initiatives going on. Based on internal thinking and with everything that’s happened, what do you think it’s like the most significant or potential strategic growth driver, at least in ’24?

Adam Levy: Unquestionably, it’s probably AbbVie. There’s going to be some other good things, but that 1 is staring us right in the face.

Naz Rahman: Got it. Do you have any thoughts on how much of that revenue — how much of your revenue that AbbVie could compromise?

Adam Levy: Again, look, the — this is — it will be very significant, we think. They paid more than $0.5 billion, $550 million for this product. I can’t imagine they’re going to go out. And again, I don’t have any direct knowledge, and I’m under NDA, but I can’t imagine they’re going to go out week with that kind of investment. So if that — if they really do the job that we think they can do on that product, that is, by far, the biggest opportunity we have.

Naz Rahman: Understood. On the prepared remarks, you commented a little about the amblyopia patch launch. Could you provide more color on what feedback you got from physicians regarding the patch. And I was also curious in terms of the actual use of the patch, have you found that they’re being mainly given to, I guess, new patients or switches. And do you have any idea of how many patients are either new or which is like in terms of percentages?

Adam Levy: So great question. So as far as so far, the feedback has been terrific. Generally, they’re being given to existing patients because the patients with the worst irritation and the worst issues are the ones that were using a different patch. The children are complaining. They’ve got those red rings around their eyes that are either blistering or were very irritated. So those are who I think the doctors are giving it to first and foremost, and then they’re going to offer it to other people. And as the practice goes through, patients come in every month to get a different set in. They seem to be now steadily reordering and steadily giving it to more and more patients. I think what we need to understand and don’t have the full picture of yet, is exactly what percentage of their patients are going to switch to this, right?

It’s a slight premium or a significant premium. Actually, it’s about 50% more expensive than something else you can buy on Amazon. And I think what we need to determine is if everybody just going to like it because it feels so much better or are really the patients that are going to use it the ones with the worst eye irritations and the worst problems. And that, of course, defines the size of the market. So getting a lot of feedback from the doctors. We’re doing a lot of research. We’re talking to some of the patients that want to tell us some great stories. And as we determine what our next step should be, that will kind of tell us where we should put our resources and how we should really try to ramp this thing.

Naz Rahman: That was helpful. And also on that point on amblyopia, have you gotten any inquiries for potentially very large wholesale orders beyond the initial orders or reorders.

Adam Levy: So no, I mean, we’ve gotten some large practice orders, practices that have ordered 100 boxes at a time but those are still small in the overall scheme of things until you get a lot of practices. I don’t think we’re quite ready yet, and that’s part of what we’re trying to determine before we engage 1 of those more expensive like professional sales forces that might go out to a whole bunch of doctors’ offices. We want to understand our product, understand the pitch understand what we’re doing because that’s not cheap to engage someone like that. But when we’re ready, that is definitely 1 of the things that we will talk about and make a plan around.